MedPath

Bio-equivalence Study

Not Applicable
Completed
Conditions
Bioequivalence
Bioavailability
Registration Number
NCT01638143
Lead Sponsor
Maastricht University Medical Center
Brief Summary

The primary objective of this study is to compare absorption of vitamin K2 (menaquinone-7) after intake of three different vitamin K2 supplements.

Detailed Description

Several manufacturers are producing vitamin K2 raw material in different forms, namely oil and powder. To ensure bioequivalence of different vitamin K2 sources, the investigators are interested to compare the bioavailability of three different vitamin K2 formulations that are already commercially available. Two different oils and one powder product will be compared in this randomized cross-over trial. The investigators hypothesize that different vitamin K2 sources give no differences in bioavailability of vitamin K2.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria
  • Healthy men and women, aged between 20 and 40 years
  • Normal body weight and height (18.5 kg/m2 < BMI < 30 kg/m2)
  • Stable body weight (weight gain or loss < 3 kg in past 3 mo)
  • Written consent to take part in the study
  • Agreement to adhere to dietary restrictions required by the protocol
Exclusion Criteria
  • Abuse of drugs and/or alcohol
  • Use of vitamin supplements containing vitamin K
  • Soy allergy
  • Pregnancy
  • a history of) metabolic or gastrointestinal diseases including hepatic disorders
  • Chronic degenerative and/or inflammatory diseases, e.g. diabetes mellitus, renal failure
  • Use of oral anticoagulants
  • Corticoid treatment
  • Subjects with anaemia or subjects who recently donated blood or plasma
  • Systemic treatment or topical treatment likely to interfere with coagulation metabolism (salicylates, antibiotics)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
MK-7 absorption profiles9 weeks

The purpose of this study is to compare the MK-7 absorption profiles after intake of three different vitamin K2 (MK-7) products that are already on the market. The main study parameter is therefore the calculated AUC value from the individual MK-7 absorption profiles.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

VitaK BV / Maastricht University Medical Center

🇳🇱

Maastricht, Netherlands

VitaK BV / Maastricht University Medical Center
🇳🇱Maastricht, Netherlands

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.